Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by NUHAD K IBRAHIM and VICENTE VALERO.
NUHAD K IBRAHIM
Connection Strength
1.826
VICENTE VALERO
  1. Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases. NPJ Breast Cancer. 2021 Mar 19; 7(1):28.
    View in: PubMed
    Score: 0.194
  2. A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. Oncologist. 2021 02; 26(2):e230-e240.
    View in: PubMed
    Score: 0.190
  3. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer. 1998 Sep 01; 83(5):1054-5.
    View in: PubMed
    Score: 0.162
  4. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018 06 01; 124(11):2299-2305.
    View in: PubMed
    Score: 0.158
  5. Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. J Cancer. 2017; 8(11):2004-2009.
    View in: PubMed
    Score: 0.150
  6. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun. 2024 Oct 01; 4(10):2823-2834.
    View in: PubMed
    Score: 0.062
  7. Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention. Eur J Breast Health. 2023 Oct; 19(4):267-273.
    View in: PubMed
    Score: 0.058
  8. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023; 15:17588359231189422.
    View in: PubMed
    Score: 0.057
  9. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023 Jun 21; 15(13).
    View in: PubMed
    Score: 0.057
  10. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2023 Jun; 199(3):457-469.
    View in: PubMed
    Score: 0.056
  11. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5).
    View in: PubMed
    Score: 0.052
  12. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer. 2001 Feb 15; 91(4):664-71.
    View in: PubMed
    Score: 0.048
  13. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest. 2001; 19(5):459-66.
    View in: PubMed
    Score: 0.048
  14. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol. 2000 Apr; 23(2):117-21.
    View in: PubMed
    Score: 0.045
  15. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet. 2000 Jan 22; 355(9200):281-3.
    View in: PubMed
    Score: 0.045
  16. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer. 1999 Oct 01; 86(7):1251-7.
    View in: PubMed
    Score: 0.044
  17. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394.
    View in: PubMed
    Score: 0.043
  18. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer. 2019 06; 120(12):1105-1112.
    View in: PubMed
    Score: 0.043
  19. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515.
    View in: PubMed
    Score: 0.037
  20. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat. 2016 07; 158(1):67-77.
    View in: PubMed
    Score: 0.035
  21. Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clin Breast Cancer. 2015 Oct; 15(5):325-31.
    View in: PubMed
    Score: 0.032
  22. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7.
    View in: PubMed
    Score: 0.030
  23. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):631-6.
    View in: PubMed
    Score: 0.027
  24. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20; 30(9):930-5.
    View in: PubMed
    Score: 0.026
  25. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34.
    View in: PubMed
    Score: 0.025
  26. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer. 2004 Oct 01; 101(7):1508-13.
    View in: PubMed
    Score: 0.015
  27. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004 Jun 15; 22(12):2284-93.
    View in: PubMed
    Score: 0.015
  28. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004 Feb 07; 25(3):94-102.
    View in: PubMed
    Score: 0.015
  29. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol. 2002 Feb; 13(2):218-21.
    View in: PubMed
    Score: 0.013
  30. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001 Oct 01; 92(7):1775-82.
    View in: PubMed
    Score: 0.013
  31. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol. 2001 Jul 15; 19(14):3422-33.
    View in: PubMed
    Score: 0.012
  32. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999 Nov; 17(11):3412-7.
    View in: PubMed
    Score: 0.011
  33. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer. 1998 Mar 01; 82(5):965-9.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.